The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Tumor PD-L1 expression and gene panel mutational profile as outcome predictors of PD-1-based checkpoint inhibition therapy in metastatic melanoma: A prospective multicenter DeCOG study.
 
Selma Ugurel
Honoraria - Bristol-Myers Squibb; Merck Serono; Merck Sharp & Dohme; Novartis; Roche
Consulting or Advisory Role - Bristol-Myers Squibb; Merck Serono; Roche
Research Funding - Bristol-Myers Squibb (Inst); Merck Serono (Inst)
Travel, Accommodations, Expenses - Bristol-Myers Squibb; Merck Sharp & Dohme; Novartis; Roche
 
Klaus Griewank
Patents, Royalties, Other Intellectual Property - Exon 4 mutations in GNAQ and GNA11 A rare gene mutation in melanoma, I receive annual payments (around 100 dollars 2016)
Travel, Accommodations, Expenses - Roche
 
Susanne Horn
No Relationships to Disclose
 
Rudolf Herbst
Employment - Helios Kliniken
 
Patrick Terheyden
Honoraria - Bristol-Myers Squibb; CureVac; Merck Serono; MSD Oncology; Novartis; Roche
Consulting or Advisory Role - Bristol-Myers Squibb; Merck KGaA; Novartis; Pierre Fabre; Roche; Sanofi
Travel, Accommodations, Expenses - Bristol-Myers Squibb; Pierre Fabre
 
Jochen Utikal
Stock and Other Ownership Interests - BioNTech; Merck; Moderna Therapeutics; Pfizer; Sanofi
Honoraria - Bristol-Myers Squibb; MSD Oncology; Novartis; Pierre Fabre; Roche; Sanofi
Consulting or Advisory Role - Amgen; Bristol-Myers Squibb; MSD Oncology; Novartis; Pierre Fabre; Roche; Sanofi
Research Funding - Apogenix (Inst); Elsalys Biotech (Inst); Noxxon Pharma (Inst); TILT Biotherapeutics (Inst)
Travel, Accommodations, Expenses - Amgen; Bristol-Myers Squibb; MSD Oncology; Novartis; Pierre Fabre; Roche; Sanofi
 
Claudia Pföhler
Honoraria - Abbvie; Bristol-Myers Squibb; Celgene; Leo Pharma; Merck Serono; Merck Sharp & Dohme; Novartis; Roche
Consulting or Advisory Role - Merck Serono; Novartis; Roche
Travel, Accommodations, Expenses - Abbvie; Bristol-Myers Squibb; Celgene; Leo Pharma; Merck Serono; Merck Sharp & Dohme; Novartis; Roche
 
Jens Ulrich
Consulting or Advisory Role - BMS; Sanofi/Regeneron
Speakers' Bureau - Bristol-Myers Squibb
Research Funding - NOVARTIS (Inst)
Travel, Accommodations, Expenses - Bristol-Myers Squibb; Medac; SUN Pharma
 
Alexander Kreuter
No Relationships to Disclose
 
Peter Mohr
Honoraria - Amgen; Bristol-Myers Squibb; Merck; Merck Sharp & Dohme; Novartis; Pierre Fabre; Roche/Genentech; Sanofi
Consulting or Advisory Role - Amgen; Bristol-Myers Squibb; Merck; Merck Sharp & Dohme; Novartis; Pierre Fabre; Roche; Sanofi
Speakers' Bureau - Amgen; Bristol-Myers Squibb; Merck Sharp & Dohme; Novartis; Roche; Sanofi
Research Funding - Bristol-Myers Squibb (Inst); Merck Sharp & Dohme (Inst); Novartis (Inst)
Travel, Accommodations, Expenses - Amgen; Bristol-Myers Squibb; Merck Sharp & Dohme; Novartis; Pierre Fabre; Roche; Sanofi; Sun Pharma
 
Ralf Gutzmer
Honoraria - Almirall Hermal GmbH; Amgen; Bayer; Bristol-Myers Squibb; Immunocore; Merck Serono; Merck Sharp & Dohme; Novartis; Pierre Fabre; Roche/Genentech; Sanofi/Regeneron; Sun Pharma
Consulting or Advisory Role - 4SC; Almirall Hermal GmbH; Amgen; Bristol-Myers Squibb; Immunocore; Merck Serono; Merck Sharp & Dohme; Novartis; Pierre Fabre; Roche/Genentech; Sanofi; Sun Pharma
Research Funding - Amgen (Inst); Johnson & Johnson (Inst); Merck Serono (Inst); Novartis (Inst); Pfizer (Inst); Sanofi (Inst); Sun Pharma (Inst)
Travel, Accommodations, Expenses - Bristol-Myers Squibb; Merck Serono; Pierre Fabre; Roche; Sun Pharma
 
Friedegund Elke Meier
Honoraria - Amgen; Bristol-Myers Squibb; Merck; MSD; Novartis; Roche; Sanofi
Consulting or Advisory Role - Amgen; Bristol-Myers Squibb; Merck; MSD; Novartis; Pierre Fabre; Roche; Sanofi
Research Funding - Novartis; Roche
Travel, Accommodations, Expenses - Amgen; Bristol-Myers Squibb; Merck; MSD; Novartis; Pierre Fabre; Roche; Sanofi
 
Edgar Dippel
No Relationships to Disclose
 
Antje Sucker
No Relationships to Disclose
 
Jan-Malte Placke
Honoraria - Bristol-Myers Squibb; Novartis
Travel, Accommodations, Expenses - Bristol-Myers Squibb; Therakos
 
Eva Hadaschik
No Relationships to Disclose
 
Jürgen C. Becker
Consulting or Advisory Role - Amgen; eTheRNA; InProTher; Merck Serono; Sanofi/Regeneron
Speakers' Bureau - Amgen; Merck Serono; Novartis; Sanofi/Regeneron
Research Funding - Alcedis (Inst); Amgen (Inst); Bristol-Myers Squibb (Inst); IQvia (Inst); Merck Serono (Inst)
Travel, Accommodations, Expenses - 4SC; Merck Serono
 
Michael Weichenthal
Honoraria - Bristol-Myers Squibb; Kyowa Hakko Kirin; Medac; Merck Sharp & Dohme; Novartis; Roche
Consulting or Advisory Role - Bristol-Myers Squibb; Merck Sharp & Dohme; Novartis; Pierre Fabre; Roche; Sanofi; Sun Pharma; Takeda
Research Funding - Bristol-Myers Squibb (Inst); Johnson & Johnson (Inst); Merck Sharp & Dohme (Inst); Millennium (Inst); Novartis (Inst)
Travel, Accommodations, Expenses - Amgen; Bristol-Myers Squibb; Merck Sharp & Dohme; Novartis; Pierre Fabre
 
Dirk Schadendorf
Honoraria - 4SC; Array BioPharma; Bristol-Myers Squibb; Immunocore; InflarxGmbH; Merck Serono; Merck Sharp & Dohme; NeraCare GmbH; Novartis; Pfizer; Philogen; Pierre Fabre; Regeneron; Roche/Genentech; Sandoz; Sanofi/Regeneron; Sun Pharma; Ultimovacs
Consulting or Advisory Role - 4SC; Bristol-Myers Squibb; Merck Serono; Merck Sharp & Dohme; NEKTAR; Novartis; Pierre Fabre; Roche/Genentech; Sanofi/Regeneron
Speakers' Bureau - Bristol-Myers Squibb; Merck KGaA; Merck Sharp & Dohme; Novartis; Pierre Fabre; Sanofi/Regeneron
Research Funding - Array BioPharma/Pfizer (Inst); Bristol-Myers Squibb (Inst); MSD Oncology (Inst); Novartis (Inst); Roche (Inst)
Travel, Accommodations, Expenses - Bristol-Myers Squibb; Merck Serono; Merck Sharp & Dohme; Novartis; Pierre Fabre; Roche/Genentech; Sanofi/Regeneron